講座編號(hào)：jz-yjsb-2021-y039

講座題目：Advanced in Vitro Test Systems in Respiratory Toxicology

主 講 人：張全順 研究員 美國(guó)體外科學(xué)研究院

講座時(shí)間：2021年10月13日（星期三）上午10:00

講座地點(diǎn)：阜成路校區(qū)教三樓334室

參加對(duì)象：化妝品專(zhuān)業(yè)的研究生、本科生和教師

主辦單位：化學(xué)與材料工程學(xué)院、研究生院

主講人簡(jiǎn)介：

張全順，資深毒理學(xué)科學(xué)家，畢業(yè)于南京農(nóng)業(yè)大學(xué)，現(xiàn)任美國(guó)體外科學(xué)研究所（Institute for In Vitro Sciences，IIVS）教育和外聯(lián)項(xiàng)目科學(xué)計(jì)劃主任。張全順博士曾在上海出入境檢驗(yàn)檢疫局從事產(chǎn)品毒理學(xué)檢測(cè)及臨床安全評(píng)價(jià)工作，有十年的海關(guān)檢疫工作經(jīng)驗(yàn)，2000年在美國(guó)普洛威頓斯學(xué)院和塔夫茨大學(xué)從事產(chǎn)品安全檢測(cè)和臨床評(píng)價(jià)的研究工作，積累了豐富的化妝品產(chǎn)品研發(fā)，安全和功效評(píng)價(jià)經(jīng)驗(yàn)。目前他負(fù)責(zé)的化妝品體外安全功效評(píng)價(jià)教育和外聯(lián)項(xiàng)目主要在中國(guó)，巴西和俄羅斯進(jìn)行。

主講內(nèi)容：

The Family Smoking Prevention and Tobacco Control Act of 2009 facilitated the establishment of the FDA Center for Tobacco Products (CTP), and gave it regulatory authority over the marketing, manufacture and distribution of tobacco products, including those termed 'modified risk'. The 2007 report, “Toxicity Testing in the 21st Century – a Vision and a Strategy”, The National Academies Press, Washington D.C., describes a path forward for toxicology and envisions the use of more predictive human-relevant in vitro models for estimating human health risks. Aside from the ethical considerations and often poor predictive value of animal testing, the vast numbers of chemicals requiring evaluation will require a new strategy that many researchers believe depends upon the use of competent human-relevant, in vitro/ex vivo test systems applied in a pragmatic manner. Since 2013, the Institute for In Vitro Sciences, Inc. (IIVS) convened a series of workshop conferences: 1) Workshop on Inhalation Toxicity: Pathways to Better Methods (May 1-3, 2013); 2) Assessment of In Vitro COPD Models for Tobacco Regulatory Science (December 8-10, 2014); 3) Technical Workshop for Goblet Cell Hyperplasia, Mucus Production and Ciliary Beating Assays (June 16-18, 2015); and 4) In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhaled Tobacco Products (April 4-6, 2016), to bring together stakeholders representing regulatory agencies, academia and industry to address the research priorities articulated by the FDA CTP.

Collectively, In vitro models utilizing human-derived cell lines and primary cells provide endpoints that reflect cytotoxic, genotoxic, and other relevant adverse events following exposure to toxicants. More recently, the emergence of modern three-dimensional (3D) tissue culture systems of the respiratory tract provide toxicologists with test platforms that more accurately model the complex processes observed in native tissues that involve multiple cells types. Human donor-tissue derived spheroids/organoids, reconstructed human airways, and precision-cut lung slices provide conventional toxicity endpoints as well as more complex, relevant events that follow chemical exposure. The complement of multiple cell types, physiological structure, relevant toxicokinetics, and other properties of these models allow additional evaluations, including chronic-exposure related (e.g. inflammation), functional (e.g. ciliary beating assays), and other endpoints (e.g. Goblet cell hyperplasia) that can reflect more serious health complications that may lead to chronic obstructive pulmonary disease.

This presentation will provide an overview of in vitro/ex vivo pulmonary models and how they can be incorporated into a screening/testing strategy for chemicals/tobacco products that can include more complex human pulmonary adverse events that are evaluable in modern 3D systems.